Risperidone

Among patients with schizophrenia, TV-46000 had a favorable safety profile that was consistent with other formulations of risperidone and previous studies of TV-46000, according to a study published in CNS Drugs.

An investigational, weekly oral dose of risperidone for schizophrenia achieved drug levels comparable to daily Risperdal in a phase 3 study involving Lynx, a long-acting drug delivery platform developed by Lyndra Therapeutics.

A biopharmaceutical company announced it has dosed the first patient in a clinical trial of a long-acting oral treatment for schizophrenia, schizoaffective disorder and bipolar I disorder, according to a company press release.

Monthly extended-release risperidone demonstrated efficacy for improving various schizophrenia symptoms, according to study results published in Journal of Clinical Psychiatry.

Teva Pharmaceuticals and MedinCell announced FDA acceptance of a new drug application for risperidone extended-release injectable suspension for subcutaneous use, a schizophrenia treatment.

An oral, ultra-long-acting, extended-release risperidone capsule provided sustained therapeutic levels of risperidone over 1-week dosing intervals, according to results of a randomized, parallel group, placebo-controlled study.

Lumateperone appeared to significantly improve depressive symptoms among patients with a bipolar 1- or 2-associated major depressive episode, according to data presented at the American Society of Clinical Psychopharmacology Annual Meeting.

Clinicians should frequently monitor metabolic traits during early stages of antipsychotic treatment because of rapid and substantial changes that can occur, according to results of a randomized, open-label, pharmacologic trial published in Journal of Clinical Psychiatry.